MedTrace Logo

Study to Detect Dendritic Cell Recruitment in Human Retina

NCT06872658 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2025-03-12

No results posted yet for this study

Summary

The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of the eye) that will be relevant to diseases such as age related macular degeneration (AMD), mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD.

The main objectives of this study are:

1. Establish Optimal Method for Retinal Imaging of Dendritic Cells (DCs)
2. Safety and Tolerability of ICG infusion in normal healthy, older adult volunteers, in participants with AMD (Dry AMD with Geographic Atrophy (GA)), and in participants who have received a diagnosis of either Mild Cognitive Impairment (MCI) due to AD, or mild AD

Conditions

  • Dry Age Related Macular Degeneration
  • Mild Cognitive Impairment (MCI)
  • Alzheimer Disease

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • CHU de Quebec-Universite Laval

    collaborator OTHER

  • MindImmune Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Peter J Syder, PhD · MindImmue

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2025-11-01
Completion
2026-01-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06872658 on ClinicalTrials.gov